 |
|
Upcoming Events featuring
National CooperativeRx
|
|
 |
|
Health and Welfare Plan Management for Midsize Employers Conference
September 13-16 Las Vegas, NV
Learn more
2011 Wisconsin SHRM State Conference
October 12-14
Madison, WI
Learn more
|
|
 |
National CooperativeRx is a not-for-profit coalition founded and owned by plan sponsors to achieve higher value prescription benefits through volume purchasing, clinical solutions, actionable data and unparalleled customer service. For your sales and marketing needs, please contact us at 866-679-9479, extension 223
|
|
|
| Is cholesterol affecting your drug spend?
September is National Cholesterol Education Month. According to the National Heart Lung and Blood Institute:
"High blood cholesterol affects over 65 million Americans. It is a serious condition that increases your risk for heart disease. The higher your cholesterol level, the greater the risk. You can have high cholesterol and not know it. Lowering cholesterol levels that are too high lessens your risk for developing heart disease and reduces the chance of having a heart attack or dying of heart disease."
Heart disease is the number one cause of death in the United States according to the CDC. Add that to the report by Harvard Health Publications that 1 in 4 Americans over the age of 45 are taking a statin, and you can see that cholesterol is a big deal.
For free resources, including a risk calculator, information packets and heart-healthy recipes, visit the National Heart Lung and Blood Institute online.
|
HealthDay. Strokes are the third leading cause of death in the US, and are now affecting young people in greater numbers. People aged 15-44 experiencing a stroke jumped by more than 33% between 1995 and 2008. The CDC reports that this may be partly due to an increasing occurrence of younger people developing type 2 diabetes and high blood pressure, which are more commonly found in older adults. (Reinberg, 9/1) Full story
|
|
Consumer Reports. More than 500,000 Americans misinterpret prescription drug instructions each year. For example, a 2007 study revealed that one-third of patients didn't understand that "two tablets by mouth twice daily" meant taking four pills in a 24-hour period. Inconsistent information regarding side effects, medical jargon and small type all seem to also play a role. Consumer Reports visited 5 pharmacies for the same drug, and found varying instruction labels. Click on the link to read about the study, and their suggestions for cleaning up drug labels. (6/1) Full story
|
Kaiser Health News. A new poll found that employees weren't willing to sacrifice their health benefits in exchange for lower rates. Who likes the new health care law? As far as democrats and republicans are concerned, the partisan divide is shrinking with democrats down to only 60% in favor and republicans rising with up to 24% now favoring the new law. (Rau, 8/29) Full story
|
Consumer Reports. Newer is better? Not always. Consumer Reports revealed in a recent study that newer diabetes drugs such as Januvia and Onglyza are no better or safer than older diabetes drugs, but they are more expensive. In fact, they have been shown to be less effective. Consumer Reports recommends metformin (unless your health status prevents it), and if that fails to bring your blood sugar into normal range, they recommend you add glipizide or glimepiride. (6/1) Full story
|
|
Kaiser Health News. Federal subsidies to help laid-off workers afford COBRA insurance have ended as of Wednesday. This has raised concern as to how laid-off workers will be able to afford health care. In 2014, more than 30 million Americans will gain coverage as an expansion of Medicaid, the state-federal insurance program, but until then, some families may struggle for coverage. (Galewitz, 9/1) Full story
|
|
Drugs.com. The FTC's final report on authorized generic drugs concludes that when drug companies introduce an authorized generic version of their brand-name drug, it can reduce prices. The report also found that authorized generics have a substantial effect on the revenues of competing generic firms. When a competing generic manufacturer is given the sole right to compete against the brand-name company's generic version for the first 6 months, the presence of an authorized generic competitor reduces the first-filing generic's revenues by 40 to 52 percent, on average." (9/1) Full story
|
|
 |
|